![]() It will focus on the potential regulatory. Silverback Therapeutics is a biotech company developing treatments for cancer, fibrosis, and infectious diseases. The combined company will operate under the name ARS Pharmaceuticals and be headquartered in San Diego, California, US, after the completion of the transaction. ![]() associate Amy Feinberg and on benefits and compensation matters by Bay Area partner James Metz. ARS Pharmaceuticals has signed a definitive agreement to merge with Silverback Therapeutics in an all-stock transaction. Silverback Therapeutics, G1 Therapeutics, AbbVie, Anthenex, OncoPep, Outcomes4Me, Kyowa Kirin Pharma- ceuticals, Daiichi - Sankyo, Samsung Bioepsis Inc. associates Barrett Tenbarge, Alyssa Lattner and Julie Shin on tax matters by Bay Area partner Grace Lee, with Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang, with Washington, D.C. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Advice was also provide on intellectual property matters by Bay Area/San Diego partner Christopher Hazuka, with San Diego associate Robert Yeh on regulatory matters by Washington, D.C. Latham & Watkins LLP represents the underwriters in the transaction with a life sciences capital markets team led by Bay Area partner Brian Cuneo, with Bay Area associates Phillip Stoup, Raul Gonzalez and Taimi Jacobson. In addition, Silverback has granted the underwriters a 30-day option to purchase up to an additional 1,725,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions. ![]() All of the shares are being offered by Silverback. Novemat 4:02 PM 7 min read Over 280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and. These figures correspond to the information presents on the Traders Cheat Sheet page. ![]() The gross proceeds to Silverback from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be US$241.5 million. Glassdoor gives you an inside look at what its like to work at Silverback Therapeutics, including salaries, reviews, office photos, and more. View, at a glance, the 52-Week High and Low for a symbol, along with the 61.8, 50, and 38.2 Fibonacci levels. (Silverback), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, has announced the pricing of its initial public offering of 11,500,000 shares of its common stock at a price to the public of US$21.00 per share. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |